Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

10.3389/fonc.2014.00058

Saved in:

書目詳細資料
Main Authors:	Ou, S.-H.I, Soo, R.A, Kubo, A, Kawaguchi, T, Ahn, M.-J
其他作者:	CANCER SCIENCE INSTITUTE OF SINGAPORE
格式:	Review
出版:	2020
主題:	anaplastic lymphoma kinase brain derived neurotrophic factor receptor cabozantinib CD74 antigen crizotinib lenvatinib platelet derived growth factor alpha receptor platelet derived growth factor receptor ponatinib protein Ret protein tyrosine kinase protein tyrosine kinase A protein tyrosine kinase inhibitor Raf protein regorafenib sorafenib sunitinib vandetanib vasculotropin receptor 1 vasculotropin receptor 3 breast cancer chronic myelomonocytic leukemia clinical trial (topic) colorectal carcinoma cost effectiveness analysis DNA transfection drug approval drug industry fluorescence in situ hybridization food and drug administration gene rearrangement human immunohistochemistry lung non small cell cancer molecular diagnostics off label drug use reverse transcription polymerase chain reaction review sequence analysis sequence homology thyroid cancer
在線閱讀:	https://scholarbank.nus.edu.sg/handle/10635/183179
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

實物特徵
總結:	10.3389/fonc.2014.00058